Validation of urgency scale to detect and assess urgency in patients with overactive bladder


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Urinary urgency is a hallmark symptom of overactive bladder (OAB). Several scales have been used to measure urgency. Taking into account the exceptional importance of these scales, it is important to determine their reliability, which depends directly on the accuracy of the wording and clarity to patients. Aim. To determine reliability of Russian-language translation of the Patient Perception of Intensity of Urgency Scale (PPIUS) in identifying and assessing urgency in patients with OAB. Materials and methods. The study included 50 patients (46 women and 4 men) aged 19 to 70 years (mean age 56.5 years). At the time of entering the study, all patients had symptoms of OAB and received anticholinergic therapy for at least 3 months with any drug approved for the use in Russia. PPIUS scale validation was performed by assessing reliability, absence of "habituation" effect of and indicators of convergent, divergent, and content validity. Results. The Russian version of voiding diary with PPIUS scale was found to have good psychometric properties and besides the content validity also had significant signs of convergent and divergent validity. Conclusion. The Russian-language versions of urgency scales PPIUS and TUFS can be considered validated for using in clinical practice and in clinical and non-interventional studies in patients with OAB in Russia.

Full Text

Restricted Access

About the authors

G. G Krivoborodov

N.I. Pirogov RNRMU

Email: dr.krivoborodov@yandex.ru
Department of Surgery, Urology (Head - Academician of the RAS, Prof. A.I. Kirienko) of Medical Faculty

E. I Tur

N.I. Pirogov RNRMU

Department of Surgery, Urology (Head - Academician of the RAS, Prof. A.I. Kirienko) of Medical Faculty

References

  1. Abrams P., Cardozo L., Fall M. et al. Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003*61(1): 37-49.
  2. Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S.A. Medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. British Journal of Obstetrics and Gynaecology. 1997*104 (9): 988-993.
  3. Homma Y., Paick J.S., Lee J.G., Kawabe K. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International. 2003*92 (7): 741-747.
  4. Landis R., Koch G. The measurement of observer agreement for categorical data. Biometrics 1977* (3): 159-174.
  5. Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001* 87: 760-766.
  6. Stewart W.F., Van Rooyen J.B., Cundiff G.W. et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003*20: 327-336.
  7. Irwin D.E., Abrams P., Milsom I. et al. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int. 2008*101(11): 1381-1387.
  8. Coyne K.S., Payne C., Bhattacharyya S.K. et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004; 7: 455-463.
  9. Freeman R.M. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16: 93-95.
  10. Cartwright R., Srikrishna S., Cardozo L., Robinson D. Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder. BJU Int 2011; 107: 1612-1617.
  11. Abrams P., Artibani W., Cardozo L. et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28: 287.
  12. EMEA. Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence. 2002. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003350.pdf.
  13. Cardozo L., Mikulas G., Amarenco T. et al. Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE. Urology 2010; 76(Suppl. 3): S92. Abstract UP-2.35.
  14. Mathias S.D., Crosby R., Klaver M. et al. The patient perception of intensity of urgency scale (PPIUS): its validation in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). ISPOR 18th Annual International Meeting. 2013.
  15. Notte S.M., Marshall T.S., Lee M. et al. Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol 2012; 12: 26.
  16. Cardozo L., Hessdorfer E., Milani R. et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, risingdose trial. BJU Int 2008; 102: 1120-1127.
  17. Nitti V.W., Khullar V., van Kerrebroeck P. et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, doubleblind, placebo-controlled, phase III studies. Int J Clin Pract 2013; 67: 619-632.
  18. Chapple C.R., Kaplan S.A., Mitcheson D. et al. Randomized doubleblind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296-305.
  19. Van Kerrebroeck P., Haab F., Angulo J.C. et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage LUTS: results from a phase 2, dose-finding study (SATURN). Eur Urol 2013; 64: 398-407.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies